124 related articles for article (PubMed ID: 11471100)
1. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; McChesney MB; Aguirre NL; Schmidt KA; Bischofberger N; Marthas ML
J Infect Dis; 2001 Aug; 184(4):429-38. PubMed ID: 11471100
[TBL] [Abstract][Full Text] [Related]
2. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Van Rompay KK; Marthas ML; Lifson JD; Berardi CJ; Vasquez GM; Agatep E; Dehqanzada ZA; Cundy KC; Bischofberger N; Pedersen NC
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):761-73. PubMed ID: 9643376
[TBL] [Abstract][Full Text] [Related]
3. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
Van Rompay KK; Schmidt KA; Lawson JR; Singh R; Bischofberger N; Marthas ML
J Infect Dis; 2002 Nov; 186(10):1508-13. PubMed ID: 12404171
[TBL] [Abstract][Full Text] [Related]
4. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; Berardi CJ; Aguirre NL; Bischofberger N; Lietman PS; Pedersen NC; Marthas ML
AIDS; 1998 Jun; 12(9):F79-83. PubMed ID: 9662190
[TBL] [Abstract][Full Text] [Related]
5. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Subbarao S; Otten RA; Ramos A; Kim C; Jackson E; Monsour M; Adams DR; Bashirian S; Johnson J; Soriano V; Rendon A; Hudgens MG; Butera S; Janssen R; Paxton L; Greenberg AE; Folks TM
J Infect Dis; 2006 Oct; 194(7):904-11. PubMed ID: 16960777
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Miller MD; Marthas ML; Margot NA; Dailey PJ; Canfield DR; Tarara RP; Cherrington JM; Aguirre NL; Bischofberger N; Pedersen NC
J Virol; 2000 Feb; 74(4):1767-74. PubMed ID: 10644348
[TBL] [Abstract][Full Text] [Related]
7. Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
Smith MS; Foresman L; Lopez GJ; Tsay J; Wodarz D; Lifson JD; Page A; Wang C; Li Z; Adany I; Buch S; Bischofberger N; Narayan O
Virology; 2000 Nov; 277(2):306-15. PubMed ID: 11080478
[TBL] [Abstract][Full Text] [Related]
8. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
[TBL] [Abstract][Full Text] [Related]
9. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Cherrington JM; Marthas ML; Lamy PD; Dailey PJ; Canfield DR; Tarara RP; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1999 Apr; 43(4):802-12. PubMed ID: 10103184
[TBL] [Abstract][Full Text] [Related]
10. Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
Subbarao S; Ramos A; Kim C; Adams D; Monsour M; Butera S; Folks T; Otten RA
J Med Primatol; 2007 Aug; 36(4-5):238-43. PubMed ID: 17669212
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).
Castillo AB; Tarantal AF; Watnik MR; Martin RB
J Orthop Res; 2002 Nov; 20(6):1185-9. PubMed ID: 12472227
[TBL] [Abstract][Full Text] [Related]
12. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Van Rompay KK; Cherrington JM; Marthas ML; Berardi CJ; Mulato AS; Spinner A; Tarara RP; Canfield DR; Telm S; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2586-91. PubMed ID: 8913470
[TBL] [Abstract][Full Text] [Related]
13. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
van Rompay KK; Dailey PJ; Tarara RP; Canfield DR; Aguirre NL; Cherrington JM; Lamy PD; Bischofberger N; Pedersen NC; Marthas ML
J Virol; 1999 Apr; 73(4):2947-55. PubMed ID: 10074144
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Rosenwirth B; ten Haaft P; Bogers WM; Nieuwenhuis IG; Niphuis H; Kuhn EM; Bischofberger N; Heeney JL; Uberla K
J Virol; 2000 Feb; 74(4):1704-11. PubMed ID: 10644340
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
[TBL] [Abstract][Full Text] [Related]
16. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
17. CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques.
Monceaux V; Viollet L; Petit F; Cumont MC; Kaufmann GR; Aubertin AM; Hurtrel B; Silvestri G; Estaquier J
J Virol; 2007 Dec; 81(24):13865-75. PubMed ID: 17898067
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
19. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Tsai CC; Follis KE; Sabo A; Beck TW; Grant RF; Bischofberger N; Benveniste RE; Black R
Science; 1995 Nov; 270(5239):1197-9. PubMed ID: 7502044
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
Van Rompay KK; Kearney BP; Sexton JJ; Colón R; Lawson JR; Blackwood EJ; Lee WA; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):6-14. PubMed ID: 16810108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
